May 2025 in “The Journal of Rheumatology” A woman with skin and joint issues progressed from one type of lupus to another, highlighting the need to recognize complex conditions.
May 2025 in “The Journal of Rheumatology” Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.
May 2025 in “The Journal of Rheumatology” Trans-esophageal echocardiography is crucial for accurately diagnosing heart issues in lupus patients.
May 2025 in “The Journal of Rheumatology” Chronic granulomatous disease may be linked to developing systemic lupus erythematosus.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
May 2025 in “The Journal of Rheumatology” Proactive physical therapy improved mobility, reduced fatigue, and pain in lupus patients.
May 2025 in “The Journal of Rheumatology” Mixed Connective Tissue Disease can develop from overlapping symptoms of several autoimmune diseases, making diagnosis complex.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
May 2025 in “The Journal of Rheumatology” Early recognition and management of gastrointestinal tuberculosis in lupus patients are crucial to prevent complications.
May 2025 in “The Journal of Rheumatology” Catatonia can be a rare sign of lupus, needing careful diagnosis and treatment.
May 2025 in “The Journal of Rheumatology” Purpura fulminans can signal underlying autoimmune disorders, not just infections.
May 2025 in “The Journal of Rheumatology” Lupus patients in Ghana face healthcare challenges, and the Oyemam Autoimmune Foundation is working to improve awareness and support.
May 2025 in “The Journal of Rheumatology” Bullous lupus can cause severe esophageal issues but responds well to corticosteroids and azathioprine.
May 2025 in “The Journal of Rheumatology” Atypical symptoms in lupus can indicate different kidney issues.
May 2025 in “The Journal of Rheumatology” Correct diagnosis is crucial for treating overlapping conditions like NMOSD and SLE effectively.
May 2025 in “The Journal of Rheumatology” Middle-aged women with dilated cardiomyopathy should be screened for antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.
May 2025 in “The Journal of Rheumatology” Antiphospholipid syndrome can severely damage adrenal glands, requiring early diagnosis and treatment.
May 2025 in “The Journal of Rheumatology” SLE can cause unusual gastrointestinal symptoms, and immunosuppressive therapy can be effective.
July 2018 in “Elsevier eBooks” Some drugs can cause reversible hair loss, but certain chemotherapy drugs may lead to permanent hair loss; drugs can also change hair color and texture.
March 2014 in “Journal of The American Academy of Dermatology” The document lists various dermatology topics, treatments, and diagnostic methods.
October 2007 in “Journal of Investigative Dermatology” The document suggests a bacteria plays a significant role in acne rosacea and that white hair can regain color after transplant, meriting more research on reversing grey hair.
May 2017 in “Neurologie pro praxi” Hair loss from multiple sclerosis treatments is usually temporary.
39 citations
,
September 2015 in “Clinical Therapeutics” Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
35 citations
,
January 2022 in “Frontiers in Neurology” Effective pain management in multiple sclerosis requires individualized treatment strategies.
6 citations
,
April 2022 in “Biomedicine & pharmacotherapy” Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
January 2026 in “Open Science Framework” Some treatments for multiple sclerosis can cause hair loss.
July 2024 in “Skin Appendage Disorders” Certain medications, including some immune drugs, contraceptives, and hair loss treatments, are often linked to hair loss.
February 2009 in “Journal of the American Academy of Dermatology” December 2020 in “Forum Dermatologicum” Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.